

Description générale

INN	Didanosine
Codes ATC	J05AF02
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2002 (TRS 914) pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Retiré en 2015 (TRS 994) pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipédia	Didanosine ↗
DrugBank	Didanosine ↗

Recommandations

Section Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution

Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

